BackUnited Therapeutics Overview

United Therapeutics Accounts Payable

Track United Therapeutics's accounts payable ($500M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$497.80M

Peer trimmed avg / median

Loading

United Therapeutics Accounts Payable History

Loading

United Therapeutics vs. peers: Accounts Payable Comparison

Loading

United Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

United Therapeutics (UTHR) FAQ

United Therapeutics (UTHR) currently reports a accounts payable of $500M as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore United Therapeutics's accounts payable history and peer comparisons.

United Therapeutics's accounts payable changed from $0 to $500M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

United Therapeutics reported $500M in accounts payable as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $500M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for United Therapeutics, and consider following UTHR for alerts when major investors trade the stock.

United Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $500M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing UTHR with unrelated industries.